Evidence map›Paper›PMID 39840604›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Single Cell-Pair Proteomics for Decoding Immune-Cancer Cell Interactions.

Qin-Qin Xu, Yi-Rong Jiang, Jian-Bo Chen, Jie Wu, Yi-Xue Chen, Qian-Xi Fan, Hui-Feng Wang, Yi Yang, Jian-Zhang Pan, Qun Fang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. [Multidimensional characteristics of the tumor microenviron-ment and advances in targeted delivery strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  5. Single Cell-Pair Proteomics for Decoding Immune-Cancer Cell Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qin-Qin XuInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Yi-Rong JiangInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Jian-Bo ChenInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Jie WuInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Yi-Xue ChenInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Qian-Xi FanInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Hui-Feng WangInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Yi YangSingle-cell Proteomics Research Center, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, China.
Jian-Zhang PanInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
Qun FangInstitute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.ORCID https://orcid.org/0000-0002-6250-252X

Funding

Fundamental Research Funds for the Central Universities 226-2023-00138National Ministry of Science and Technology 2021YFA1301601National Natural Science Foundation of China 22234007National Natural Science Foundation of China 22304153Zhejiang Provincial R&D Program 2024C03144
6 · The paper itself

Abstract

The efficacy of cancer immunotherapy is significantly influenced by the heterogeneity of individual tumors and immune responses. To investigate this phenomenon, a microfluidic platform is constructed for profiling immune-cancer cell interactions at the single-cell proteomics level for the first time. Based on the platform, a comprehensive workflow is proposed for achieving accurate single-cell pairing of an immune cell and a cancer cell with low cell damage and high success rate up to 95%, cell pair co-culture, and real-time microscopic monitoring of the cell-pair interactions, cell pair retrieval, mass spectrometry-based proteomic analysis of singe cell pairs, and decoupling of the proteomic information for each cell within the cell pair with the stable-isotope labeling method. With the workflow, the interactions of single natural killer (NK) cells and single K562 tumor cells are investigated based on real-time images and single cell-pair proteomics. Notably, an identification depth of over 1000 protein groups in a single cell-pair is achieved, leading to the discovery of sub-clusters of NK cells with different functions and the identification of important biomarkers for cancer treatments. This demonstrates the unique capability of the present platform in providing substantial and comprehensive datasets for profiling immune-cancer cell interactions, discovering heterogeneous immune responses, and predicting biomarkers in the study of cancer immunotherapy.

Indexed as

Cell CommunicationKiller Cells, NaturalNeoplasmsProteomicsSingle-Cell AnalysisCoculture TechniquesHumansImmunotherapyK562 Cellsimmune‐cancer cell interactionmass spectrometrymicrofluidic analysissingle cell‐pair proteomics

Identifiers

PMID39840604
PMCPMC11923901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.